{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T11:32:35Z","timestamp":1786361555880,"version":"build-2736575974"},"reference-count":23,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","license":[{"start":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T00:00:00Z","timestamp":1777420800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>ST-segment elevation myocardial infarction (STEMI) continues to be a leading cause of cardiovascular (CV) morbidity and mortality worldwide, posing an ongoing clinical and public health burden. Although angiotensin-converting enzyme inhibitors (ACEIs) remain integral to guideline-recommended therapy following STEMI, recent evidence indicates that sacubitril\/valsartan may offer superior cardioprotective benefits. This meta-analysis aims to systematically evaluate and compare the efficacy and safety of sacubitril\/valsartan versus ACEIs in the management of patients with STEMI.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>\n                      PubMed and Cochrane databases were systematically searched from inception to July 2024 to identify randomized controlled trials (RCTs) comparing sacubitril\/valsartan and ACEIs in patients with STEMI. Data were synthesized using a random-effects model to calculate risk ratios (RRs) and weighted mean differences (WMDs), each with 95% confidence intervals (CIs). A\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      -value &lt; 0.05 was considered statistically significant.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      A total of five RCTs comprising 4915 participants were included in the final analysis. Sacubitril\/valsartan therapy was associated with a significant reduction in major adverse cardiovascular events (MACE) [RR: 0.66 (0.50, 0.86);\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      =\u00a00.002] and hospitalizations for heart failure (HHF) [RR: 0.67 (0.49, 0.92);\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      =\u00a00.01]. Treatment with sacubitril\/valsartan also significantly improved left ventricular ejection fraction (LVEF) [WMD: 2.60 (1.53, 3.68);\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.00001] and reduced NT-proB-type natriuretic peptide (NT-proBNP) levels (WMD:\u00a0\u2212268.89 [\u2212422.35,\u00a0\u2212115.42];\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      =\u00a00.0006). No significant differences were observed in the risk of recurrent myocardial infarction [RR: 1.02 (0.39, 2.71);\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      =\u00a00.96), CV death [RR: 0.78 (0.61, 1.01);\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      =\u00a00.06], or all-cause mortality [RR: 0.85 (0.68, 1.06);\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      =\u00a00.15]. Safety analyses revealed no significant differences in the risk of cough [RR: 0.63 (0.15, 2.72);\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      =\u00a00.54], hypotension [RR: 1.68 (0.97, 2.91);\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      =\u00a00.06], worsening renal function [RR: 0.51 (0.22, 1.21);\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      =\u00a00.13], or hyperkalemia [RR: 0.59 (0.17, 2.01);\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      =\u00a00.40].\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Sacubitril\/valsartan therapy significantly reduces MACE and HHF and improves LVEF in patients with STEMI, without increasing the risk of adverse safety outcomes. Future well-powered randomized trials are needed to confirm these results and support clinical guideline recommendations.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/ms9.0000000000004666","type":"journal-article","created":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T03:00:08Z","timestamp":1778036408000},"page":"3445-3453","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Evaluating the effects of sacubitril\/valsartan with ST-elevated myocardial infarction: a systematic review and meta-analysis"],"prefix":"10.1097","volume":"88","author":[{"given":"Ajay","family":"Kumar","sequence":"first","affiliation":[{"name":"Department of Medicine, Shaheed Mohtarma Benazir Bhutto Medical College Lyari, Karachi, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohit","family":"Kumar","sequence":"additional","affiliation":[{"name":"Department of Medicine, Bahria University Medical Dental College, Karachi, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simran","family":"Kumari","sequence":"additional","affiliation":[{"name":"Department of Medicine, Ghulam Muhammad Mahar Medical College Sukkur, Sukkur, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Muskan","sequence":"additional","affiliation":[{"name":"Department of Medicine, Gambat Institute of Medical Sciences, Gambat, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Kashish","sequence":"additional","affiliation":[{"name":"Department of Medicine, Peoples University of Medical Health Sciences for Women(PUMHSW), Nawabshah, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aakash","family":"Kumar","sequence":"additional","affiliation":[{"name":"Department of Medicine, Shaheed Mohtarma Benazir Bhutto Medical College Lyari, Karachi, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiran","family":"Kumari","sequence":"additional","affiliation":[{"name":"Department of Medicine, Ziauddin Medical University, Karachi, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Radhika","family":"Kumari","sequence":"additional","affiliation":[{"name":"Department of Medicine, Peoples University of Medical Health Sciences for Women(PUMHSW), Nawabshah, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faraz","family":"Hussain","sequence":"additional","affiliation":[{"name":"Department of Medicine, Gambat Institute of Medical Sciences, Gambat, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Simran","sequence":"additional","affiliation":[{"name":"Department of Medicine, Isra University, Hyderabad, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sayed","family":"Jawad","sequence":"additional","affiliation":[{"name":"Department of Medicine, Kabul University of Health Sciences, Kabul, Afghanistan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,4,29]]},"reference":[{"key":"R1-20260810","doi-asserted-by":"crossref","first-page":"527\u201331","DOI":"10.1001\/jamacardio.2017.5356","article-title":"In-hospital ST-segment elevation myocardial infarction: improving diagnosis, triage, and treatment","volume":"3","author":"Levine","year":"2018","journal-title":"JAMA Cardiol"},{"key":"R2-20260810","doi-asserted-by":"crossref","first-page":"101005","DOI":"10.1016\/j.cpcardiol.2021.101005","article-title":"Trends in clinical characteristics and outcomes in ST-elevation myocardial infarction hospitalizations in the United States, 2002-2016","volume":"47","author":"Ahuja","year":"2022","journal-title":"Curr Probl Cardiol"},{"key":"R3-20260810","doi-asserted-by":"crossref","first-page":"e362","DOI":"10.1161\/CIR.0b013e3182742c84","article-title":"2013 ACCF\/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation\/American Heart Association task force on practice guidelines","volume":"127","author":"O\u2019Gara","year":"2013","journal-title":"Circulation"},{"key":"R4-20260810","doi-asserted-by":"crossref","first-page":"1893\u2013906","DOI":"10.1056\/NEJMoa032292","article-title":"Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both","volume":"349","author":"Pfeffer","year":"2003","journal-title":"N Engl J Med"},{"key":"R5-20260810","doi-asserted-by":"crossref","first-page":"7\u201313","DOI":"10.1016\/j.amjcard.2020.12.037","article-title":"Comparison of the efficacy and safety of sacubitril\/valsartan versus ramipril in patients with ST-segment elevation myocardial infarction","volume":"143","author":"Rezq","year":"2021","journal-title":"Am J Cardiol"},{"key":"R6-20260810","doi-asserted-by":"crossref","first-page":"427\u201331","DOI":"10.1097\/MCA.0000000000000955","article-title":"Benefits of early administration of Sacubitril\/Valsartan in patients with ST-elevation myocardial infarction after primary percutaneous coronary intervention","volume":"32","author":"Zhang","year":"2021","journal-title":"Coron Artery Dis"},{"key":"R7-20260810","doi-asserted-by":"crossref","first-page":"42\u201354","DOI":"10.21037\/cdt-21-386","article-title":"Comparing the efficacy of angiotensin receptor-neprilysin inhibitor and enalapril in acute anterior STEMI patients after primary percutaneous coronary intervention: a prospective randomized trial","volume":"12","author":"Dong","year":"2022","journal-title":"Cardiovasc Diagn Ther"},{"key":"R8-20260810","doi-asserted-by":"crossref","first-page":"1017\u201327","DOI":"10.21037\/apm-22-210","article-title":"Therapeutic effects and safety of early use of sacubitril\/valsartan after acute myocardial infarction: a systematic review and meta-analysis","volume":"11","author":"Zhang","year":"2022","journal-title":"Ann Palliat Med"},{"key":"R9-20260810","doi-asserted-by":"crossref","first-page":"1237210","DOI":"10.3389\/fphar.2023.1237210","article-title":"The efficacy and safety of sacubitril\/valsartan compared with ACEI\/ARB in the treatment of heart failure following acute myocardial infarction: a systematic review and meta-analysis of randomized controlled trials","volume":"14","author":"Gao","year":"2023","journal-title":"Front Pharmacol"},{"key":"R10-20260810","first-page":"100082","article-title":"Transparency in the reporting of Artificial Intelligence \u2013 the TITAN guideline","volume":"10","author":"Agha","year":"2025","journal-title":"Prem J Sci"},{"key":"R11-20260810","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.jclinepi.2009.06.006","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration","volume":"62","author":"Liberati","year":"2009","journal-title":"J Clin Epidemiol"},{"key":"R14-20260810","doi-asserted-by":"crossref","first-page":"418\u201326","DOI":"10.1097\/MCA.0000000000000932","article-title":"Effects of sacubitril\/valsartan on ventricular remodeling in patents with left ventricular systolic dysfunction following acute anterior wall myocardial infarction","volume":"32","author":"Wang","year":"2021","journal-title":"Coron Artery Dis"},{"key":"R15-20260810","doi-asserted-by":"crossref","first-page":"904\u201314","DOI":"10.1016\/j.jacc.2024.01.002","article-title":"Angiotensin receptor-neprilysin inhibition in patients with STEMI vs NSTEMI","volume":"83","author":"Mann","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"R16-20260810","doi-asserted-by":"crossref","first-page":"863\u201369","DOI":"10.1016\/j.hrtlng.2021.07.007","article-title":"Association of N-terminal pro-brain natriuretic peptide level with adverse outcomes in patients with acute myocardial infarction: a meta-analysis","volume":"50","author":"Shen","year":"2021","journal-title":"Heart Lung J Crit Care"},{"key":"R17-20260810","doi-asserted-by":"crossref","first-page":"40\u201346","DOI":"10.15420\/cfr.2016:1:1","article-title":"The mechanism of action of LCZ696","volume":"2","author":"Menendez","year":"2016","journal-title":"Card Fail Rev"},{"key":"R18-20260810","doi-asserted-by":"crossref","first-page":"231\u201338","DOI":"10.1097\/MCA.0000000000001332","article-title":"Sacubitril\/valsartan improves the prognosis of acute myocardial infarction: a meta-analysis","volume":"35","author":"Wang","year":"2024","journal-title":"Coron Artery Dis"},{"key":"R19-20260810","doi-asserted-by":"crossref","first-page":"2685\u201386","DOI":"10.1093\/eurheartj\/ehm374","article-title":"on behalf of the OPERA investigators. STEMI and NSTEMI are two distinct pathophysiological entities: reply","volume":"28","author":"Montalescot","year":"2007","journal-title":"Eur Heart J"},{"key":"R20-20260810","doi-asserted-by":"crossref","first-page":"3558","DOI":"10.3390\/jcm11123558","article-title":"Non-STEMI vs. STEMI cardiogenic shock: clinical profile and long-term outcomes","volume":"11","author":"Mart\u00ednez","year":"2022","journal-title":"J Clin Med"},{"key":"R21-20260810","doi-asserted-by":"crossref","first-page":"1161\u201372","DOI":"10.1161\/01.CIR.81.4.1161","article-title":"Ventricular remodeling after myocardial infarction. Experimental observations and clinical implications","volume":"81","author":"Pfeffer","year":"1990","journal-title":"Circulation"},{"key":"R22-20260810","doi-asserted-by":"crossref","DOI":"10.4081\/cardio.2025.78","article-title":"Optimized HF therapy in patients with very advanced cancer in palliative care: the dosing strategies from EMPATICC trial","volume":"3","author":"Anker","year":"2025","journal-title":"Global Cardiol"},{"key":"R23-20260810","article-title":"Recurrent cardiovascular events among South Asian individuals: insights from the Baylor Scott & White DILWALE Registry","author":"Rashid","journal-title":"J Clin Lipidol"},{"key":"R24-20260810","doi-asserted-by":"crossref","first-page":"1845\u201355","DOI":"10.1056\/NEJMoa2104508","article-title":"Angiotensin receptor-neprilysin inhibition in acute myocardial infarction","volume":"385","author":"Pfeffer","year":"2021","journal-title":"N Engl J Med"},{"key":"R25-20260810","doi-asserted-by":"crossref","first-page":"e004745","DOI":"10.1161\/CIRCHEARTFAILURE.117.004745","article-title":"Incidence, predictors, and outcomes associated with hypotensive episodes among heart failure patients receiving sacubitril\/valsartan or enalapril: the PARADIGM-HF trial (Prospective comparison of angiotensin receptor neprilysin inhibitor with angiotensin-converting enzyme inhibitor to determine impact on global mortality and morbidity in heart failure)","volume":"11","author":"Vardeny","year":"2018","journal-title":"Circ Heart Fail"}],"container-title":["Annals of Medicine &amp; Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MS9.0000000000004666","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T11:01:57Z","timestamp":1786359717000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MS9.0000000000004666"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,29]]},"references-count":23,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/ms9.0000000000004666","relation":{},"ISSN":["2049-0801"],"issn-type":[{"value":"2049-0801","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,29]]},"assertion":[{"value":"2025-05-24","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-30","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}